| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | 706 | 51.850 | 59.358 | 60.578 | 8.851 | 16.647 | 0 |
| Total Income - EUR | - | - | - | 706 | 51.862 | 59.358 | 60.578 | 8.851 | 16.647 | 0 |
| Total Expenses - EUR | - | - | - | 263 | 17.912 | 55.931 | 23.890 | 8.513 | 11.603 | 8.748 |
| Gross Profit/Loss - EUR | - | - | - | 443 | 33.950 | 3.427 | 36.689 | 338 | 5.043 | -8.748 |
| Net Profit/Loss - EUR | - | - | - | 421 | 33.390 | 2.905 | 36.191 | 252 | 4.877 | -8.748 |
| Employees | - | - | - | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
Check the financial reports for the company - Novel Labs S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | 96 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Assets | - | - | - | 641 | 38.647 | 81.244 | 53.406 | 15.122 | 21.356 | 15.119 |
| Inventories | - | - | - | 33 | 358 | 1.940 | 1.321 | 1.187 | 1.937 | 1.926 |
| Receivables | - | - | - | 0 | 219 | 10.135 | 1.247 | 2.039 | 11.023 | 10.961 |
| Cash | - | - | - | 607 | 38.070 | 69.169 | 50.838 | 11.896 | 8.396 | 2.231 |
| Shareholders Funds | - | - | - | 464 | 33.845 | 27.838 | 51.283 | 11.138 | 15.981 | 7.144 |
| Social Capital | - | - | - | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | - | 272 | 4.802 | 53.406 | 2.123 | 3.984 | 5.375 | 7.975 |
| Income in Advance | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4645 - 4645" | |||||||||
| CAEN Financial Year |
4645
|
|||||||||
Comments - Novel Labs S.r.l.